Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Trogarzonon May 02, 2023 3:19pm
93 Views
Post# 35425829

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nothing like some 'leaks' on the FDA Resubmission

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nothing like some 'leaks' on the FDA ResubmissionIn my opinion they only have interest for they're large shareholders since they haven't been there for too long and haven't paid 5$+ for their shares.  For instance a player like Soleus might have put 20M in Thera @ 2$ and could accept and participate some more in a cheap dilution and wait another 5yrs to see possible fruition to their investment.  The small long time players will be outraged by this and won't endorse any of this so why even bother probably.  On their end they will just vote themselves outragous new amounts of options and have a chance of making something one day while we're diluted to oblivion.  That's what I think.
<< Previous
Bullboard Posts
Next >>